Drug Trial Radar · NCT06163430
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
330
Planned (sponsor's estimate)
Start
Mar 26, 2024
Primary completion
Nov 30, 2029
Study completion May 31, 2030
Sponsor
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Dec 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer. The goal of this study is to learn about the safety of different doses (amounts) of MK-4208 (Tern-701) and if people tolerate them. Researchers also want to find the highest dose of MK-4208 (Tern-701) that people can tolerate and may work to treat blood cancer.
Conditions
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Chronic Myeloid Leukemia, Chronic Phase
- Chronic Myeloid Leukemia
Interventions
MK-4208Drug
40 mg and 100 mg oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence of Dose Limiting Toxicities (DLTs) During the First Cycle of InterventionTime frame: Up to 28 days
- Parts 1, 2m and 3: Number of Participants with at Least One AETime frame: Up to 3 years
- Parts 1, 2m and 3: Number of Participants with at Least One Serious Adverse Event (SAE)Time frame: Up to 3 years
- Parts 1, 2m and 3: Number of Participants who Discontinued Study Intervention Due to an AETime frame: Up to 3 years
- Parts 2, 2m and 3: Number of Participants with a Complete Hematologic Response (CHR)Time frame: Baseline and up to 3 years
- Parts 2, 2m and 3: Number of Participants with a Molecular response (MR)Time frame: Baseline and up to 3 years
- Parts 2, 2m and 3: Number of Participants who had Best Categorical Shift in BCR-ABL1 Transcript Levels From BaselineTime frame: Baseline and up to 3 years
Locations
54 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama Medicine (UAB Medicine)
Birmingham, Alabama · Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
UC Irvine Health
Orange, California · Recruiting
Rocky Mountain Cancer Centers, LLP
Lone Tree, Colorado · Recruiting
Florida Cancer Specialists - South Region Research Office
Fort Myers, Florida · Not yet recruiting
Florida Cancer Affiliates - Ocala
Ocala, Florida · Recruiting
Florida Cancer Specialists - North Region Research Office
St. Petersburg, Florida · Not yet recruiting
Florida Cancer Specialists - East Region Research Office
West Palm Beach, Florida · Not yet recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia · Recruiting
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York · Recruiting
Atrium Health Levine Cancer Institute
Winston-Salem, North Carolina · Recruiting
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Thomas Jefferson University - Center City (Philadelphia)
Philadelphia, Pennsylvania · Recruiting
Tristar BMT
Nashville, Tennessee · Recruiting
The University of Texas M.D. Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Monash Medical Centre
Clayton, Victoria, Australia · Not yet recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Not yet recruiting
Royal Perth Hospital
Perth, Western Australia, Australia · Recruiting
Institut Bergonié
Bordeaux, France · Recruiting
Institut Paoli Calmettes
Marseille, France · Recruiting
CHU de Nantes (University Hospital of Nantes) - Hôtel Dieu
Nantes, France · Recruiting
Hôpital Saint Louis
Paris, France · Recruiting
Centre Hospitalier Lyon-Sud
Pierre-Bénite, France · Recruiting
Centre Léon Bérard
Lyon, Auvergne-Rhône-Alpes, France · Recruiting
Universitätsklinikum Aachen
Aachen, Germany · Recruiting
Charité Campus Virchow-Klinikum - Universitätsmedizin Berlin
Berlin, Germany · Recruiting
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany · Recruiting
Medizinische Hochschule Hannover
Hanover, Germany · Recruiting
Universitätsklinikum Jena
Jena, Germany · Recruiting
Universitätsklinikum Mannheim
Mannheim, Germany · Recruiting
Klinikum rechts der lsar der Technischen Universität München
München, Germany · Recruiting
Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
Bologna, Italy · Recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy · Recruiting
Fondazione IRCCS San Gerardo dei Tintori - SC Centro di Ricerca Fase I
Monza, Italy · Recruiting
Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy · Recruiting
Auckland City Hospital
Auckland, New Zealand · Not yet recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.